hero image
Jigarkumar Parikh - Augusta University. Augusta, GA, US

Jigarkumar Parikh Jigarkumar Parikh

Co-Leader, Genito-Urinary Oncology Program | Georgia Cancer Center at Augusta University

Augusta, GA, UNITED STATES

Medical oncologist specializing in kidney cancer, prostate cancer, bladder cancer and melanoma.

Spotlight

Multimedia

Publications:

Documents:

Photos:

loading image

Videos:

Audio:

Social

Biography

Dr. Jigarkumar Parikh graduated from Baroda Medical College in India and completed his Bachelor of Medicine and Bachelor of Surgery in 2002. He was a resident in Pathology at Baroda Medical College from 2003 to 2005. Dr. Parikh completed his residency in Internal Medicine and fellowship in Hematology and Oncology at Augusta University, prior to joining the faculty as Assistant Professor if Medicine in 2014. He received the Exemplary Teaching award for medical student education for 2015-2016 and 2016-2017.

Dr. Parikh has become a member of multiple professional societies over his career. In 2008, he come a member of the National Comprehensive Cancer Network and American College of Physicians. In 2011, he became a member of American Society of Hematology and American Society of Clinical Oncology.

Areas of Expertise (9)

Oncology

Bone Cancer

Bladder Cancer

Kidney Cancer

Melanoma

Prostate Cancer

Testicular Cancer

Soft Tissue Sarcoma

Cancer

Media Appearances (3)

Local dermatologists raising awareness of sunscreen laws as new school year approaches

News 12 NBC 26  tv

2017-07-19

Dr. Jigarkumar Parikh talks with Ben Billmyer, a reporter at News 12 NBC 26, about the skin cancer concerns he wants student athletes to be aware of when they are outside practicing. Dr. Parikh. His advice - always keep water and sunscreen packed and ready to go the gym bag just in case.

view more

Drug combination helps woman in bladder cancer fight

The Augusta Chronicle  

2017-05-31

Julie Cole and her oncologist, Dr. Jigarkumar Parikh of the Georgia Cancer Center at Augusta University, decided to add a second “checkpoint inhibitor” drug and then also two weeks of radiation therapy at the original cancer site to help create an even bigger immune response, despite there being very little scientific literature to support it...

view more

Skin cancer survivor shares her story to help spread awareness

WRDW  

2017-05-09

"Skin cancer? of all the cancers, that is one that I would have never thought of," Carter said. "I'm black, I don't lay out in the tanning beds, I mean, I go to the beach or whatever, but I put sunscreen on. It's something I wouldn't think about." But for Dr. Jigarkumar Parikh with the Georgia Cancer Center, this isn't news. "People always think that this is a cancer that is most common in the white population, but it's actually not uncommon in African-Americans as well," Dr. Parikh said. He also says getting it in the toenail is also not uncommon...

view more

Articles (2)

Recurrent adult choroid plexus carcinoma treated with high-dose chemotherapy and syngeneic stem cell (bone marrow) transplant Journal of Neurological Surgery Part A: Central European Neurosurgery

Samuel TA., Parikh J., Sharma S., Giller CA., Sterling K., Kapoor S., Pirkle C., Jillella A.

2013 Choroid plexus carcinomas (CPCs) are rare epithelial central nervous system tumors. CPC occurs mainly in infants and young children, comprising ≈ 1 to 4% of all pediatric brain neoplasms. There is very limited information available regarding tumor biology and CPC treatment due to its rarity. There have been various case reports and meta-analyses of reported cases with CPC. Surgical resection is often challenging but remains a well-established treatment option. Chemotherapy is often reserved for recurrent or refractory cases, but the goal of treatment is usually palliative. We present a case of recurrent, adult CPC with disseminated leptomeningeal involvement treated with salvage chemotherapy including high-dose ifosfamide, carboplatin, and etoposide; once a remission was achieved, this response was consolidated with a syngeneic stem cell (bone marrow) transplant after a preparative regimen of high-dose chemotherapy with carboplatin, etoposide, and thiotepa. Although the patient tolerated the transplant well and remained disease-free for 12 months, she subsequently succumbed to relapsed disease 18 months posttransplant. We believe that this is the first report of using syngeneic stem cell transplant in CPC to consolidate a remission achieved by salvage chemotherapy.

view more

Lack of clustering of SCD complications into two distinct subphenotypes in an adult patient population Blood

Parikh J., Kochaparambil T., Xu H., Clair B., Natarajan K., Ustun C., Kutlar, A.

2010 The complex pathophysiologic mechanisms that contribute to disease pathology in sickle cell disease (SCD) include microvascular occlusion secondary to deoxy-Hb S polymerization, interaction of sickle RBCs with vascular endothelium and other blood cells, hemolysis with resultant nitric oxide (NO) scavenging, endothelial activation with inflammation, and activation of coagulation. It has been recently hypothesized that there may be two distinct sub-phenotypes in SCD: one where hemolysis and NO depletion predominates (hemolysis/endothelial dysfunction) and the other where vaso-occlusion and increased whole blood viscosity plays a more prominent role. The clinical complications of SCD thus cluster into one of the two subphenotypes: pulmonary hypertension, priapism, leg ulcers and stroke appear to be more commonly associated with the hemolysis/NO depletion/endothelial dysfunction subphenotype, whereas frequent pain episodes, acute chest syndrome, osteonecrosis and retinopathy tend to be more common in the viscosity/vaso-occlusion group. We had previously analyzed the records of 124 patients with Hb SS or S-b° thalassemia followed at the Medical College of Georgia Adult Sickle Cell Clinic to validate the clustering of disease complications into the aforementioned two sub-phenotypes and found no significant associations between phenotypes within each sub-group, as well as between phenotypes across the groups (all p values >0.1).

view more